On January 8, 2025, Gautam Patel, a Director at Amneal Pharmaceuticals Inc (AMRX, Financial), sold 62,590 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 1,968,886 shares of the company.
Amneal Pharmaceuticals Inc (AMRX) is a pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products. The company operates in the United States and internationally, providing a wide range of products across various therapeutic areas.
The insider transaction history for Amneal Pharmaceuticals Inc shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 9 insider sells over the same timeframe. Over the past year, Gautam Patel has sold 80,000 shares in total and purchased 0 shares in total.
Shares of Amneal Pharmaceuticals Inc were trading for $8.01 apiece on the day of Gautam Patel’s recent sell. This gives the stock a market cap of $2.469 billion. With a price of $8.01 and a GuruFocus Value of $2.49, Amneal Pharmaceuticals Inc has a price-to-GF-Value ratio of 3.22. This means the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus that is calculated based on the following three factors:
- Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
